PepGen reports positive FREEDOM2-DM1 10 mg/kg data, proposes $125M stock offering
The company said the dose cohort hit the highest splicing correction yet reported in a multiple-dose study, as its highest dose cohort finished enrolling and cash reached $104.8 million.
SEC filing (4)